Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

vitespen

An autologous cancer vaccine derived from tumor-specific gp96 heat shock proteins. Heat shock proteins chaperone peptides through the endoplasmic reticulum, are key regulators of dendritic cell maturation, migration and antigen processing, and are involved in T-cell activation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous gp96 heat shock protein peptide complex vaccine gp96 HSP-peptide complex heat shock protein peptide complex-96
US brand name:	Oncophage
Code name:	HSPPC-96

vitespen

Search NCI's Drug Dictionary